Logo-jrcm
J Anal Res Clin Med. 2016;4(2): 110-114.
doi: 10.15171/jarcm.2016.018
  Abstract View: 1326
  PDF Download: 737

Original Article

Cytochrome P4502C19*3 allelic variant frequency in Iranian healthy Azeri Turkish population

Nasim Alsadat Didevar 1, Gholamreza Niaei 2*, Majid Farshdousti Hagh 3, Bita Amir Taghavi 4

1 Department of Biology, Islamic Azad University, Tabriz Sciences and Research Branch, Tabriz, Iran
2 Department of Biology, School of Sciences, University of Guilan, Rasht, Iran
3 Associate Professor, Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4 Department of Genetics, Islamic Azad University, Tehran Medical Branch, Tehran, Iran
*Corresponding Author: Email: Gniaei@gmail.com

Abstract

Introduction: Cytochrome P4502C19 (CYP2C19) is well-known to be one of the determinants responsible for the pronounced interethnic and individual differences in response and character of clinically important drugs. CYP2C19*3 arises from a G to A transition at position 636 in exon 4 of CYP2C19. These individuals be situated poor metabolizers (PMs) of a wide range of medications including omeprazole (OMP). In this study, we determined genotypes of CYP2C19*3 in Iranian Azeri Turkish population to compare allele frequencies with previous findings in other ethnic groups. Methods: CYP2C19*3 allelic variant was determined in 200 unrelated healthy Iranian volunteers by polymerase chain reaction-restriction fragment length polymorphism assays (PCR-RFLP). Results: The frequencies of CYP2C19*3 in healthy volunteers reported in this study (P = 0.569, χ2 = 2.35). This is not higher than that would be predicted from the genotypic status of these cases in CYP2C19*3 allelic variants. Our results revealed that 95.46% had wild type allele, they did not carry any of the tested mutations and 9 (4.54%) had mutant alleles. Conclusion: Our data recommend that genotyping for CYP2C19*3 is interest in using pharmacokinetics to individualize medicine, but results of this study demonstrated that CYP2C19*3 genetic polymorphism is not important determinant of the efficacy of PM of drugs, such as OMP, which may be metabolized by this enzyme.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 1327

Your browser does not support the canvas element.


PDF Download: 737

Your browser does not support the canvas element.

Submitted: 05 Jan 2016
Accepted: 14 Feb 2016
ePublished: 09 May 2016
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)